AIRLINK 77.84 Decreased By ▼ -2.55 (-3.17%)
BOP 4.87 Decreased By ▼ -0.05 (-1.02%)
CNERGY 4.28 Decreased By ▼ -0.07 (-1.61%)
DFML 45.00 Decreased By ▼ -0.51 (-1.12%)
DGKC 85.97 Decreased By ▼ -2.83 (-3.19%)
FCCL 22.45 Decreased By ▼ -1.11 (-4.71%)
FFBL 32.00 Decreased By ▼ -1.00 (-3.03%)
FFL 9.50 Decreased By ▼ -0.07 (-0.73%)
GGL 10.09 Decreased By ▼ -0.18 (-1.75%)
HASCOL 6.55 Decreased By ▼ -0.16 (-2.38%)
HBL 112.00 Decreased By ▼ -1.00 (-0.88%)
HUBC 141.20 Decreased By ▼ -1.36 (-0.95%)
HUMNL 10.97 Decreased By ▼ -0.93 (-7.82%)
KEL 4.85 Decreased By ▼ -0.19 (-3.77%)
KOSM 4.35 Decreased By ▼ -0.15 (-3.33%)
MLCF 38.25 Decreased By ▼ -0.68 (-1.75%)
OGDC 128.89 Decreased By ▼ -3.11 (-2.36%)
PAEL 25.51 Decreased By ▼ -0.24 (-0.93%)
PIBTL 6.36 Decreased By ▼ -0.21 (-3.2%)
PPL 117.50 Decreased By ▼ -2.05 (-1.71%)
PRL 25.80 Decreased By ▼ -0.30 (-1.15%)
PTC 13.74 Decreased By ▼ -0.32 (-2.28%)
SEARL 57.09 Decreased By ▼ -0.42 (-0.73%)
SNGP 64.99 Decreased By ▼ -1.11 (-1.68%)
SSGC 10.00 Decreased By ▼ -0.19 (-1.86%)
TELE 8.12 Decreased By ▼ -0.20 (-2.4%)
TPLP 10.35 Decreased By ▼ -0.21 (-1.99%)
TRG 65.24 Decreased By ▼ -2.91 (-4.27%)
UNITY 26.85 Decreased By ▼ -0.28 (-1.03%)
WTL 1.34 Decreased By ▼ -0.01 (-0.74%)
BR100 7,831 Decreased By -100.6 (-1.27%)
BR30 25,235 Decreased By -513.8 (-2%)
KSE100 74,667 Decreased By -908.6 (-1.2%)
KSE30 23,919 Decreased By -292.9 (-1.21%)
Markets

Rand falls as South Africa puts AstraZeneca vaccinations on hold

  • South Africa had hoped to roll out the AstraZeneca vaccine to healthcare workers soon after receiving 1 million doses produced by the Serum Institute of India on Feb. 1.
Published February 8, 2021

JOHANNESBURG: South Africa's rand weakened early on Monday after the country's COVID-19 vaccination plan suffered a setback over the weekend as the government put on hold the use of AstraZeneca's vaccine in its programme.

At 0635 GMT, the rand traded at 14.8850 against the US dollar, 0.32% weaker than its close on Friday.

Health Minister Zweli Mkhize said on Sunday the government would await advice from scientists on how best to proceed after a trial showed the AstraZeneca vaccine did not significantly reduce the risk of mild or moderate COVID-19 infection caused by the country's dominant coronavirus variant.

"The government is scrambling to figure out its 'next steps' after new evidence showed that AstraZeneca's vaccine provides minimal protection against 501Y.V2 variant," analysts at NKC African Economics said in a note.

South Africa had hoped to roll out the AstraZeneca vaccine to healthcare workers soon after receiving 1 million doses produced by the Serum Institute of India on Feb. 1.

In fixed income, the yield on the benchmark instrument due in 2030 was up 1.5 basis points to 8.47% in early deals.

Comments

Comments are closed.